Home›Oncology› Lipid metabolism reprogramming emerges as key mechanism of endocrine resistance in ER+ breast cancer
Lipid metabolism reprogramming emerges as key mechanism of endocrine resistance in ER+ breast cancerFat metabolism changes help breast cancer cells resist treatment
Frontiers in MedicinePublished September 13, 2026Study authors: Zhiqi Sui, Xiaoxi Han, Shaochun Liu, Yuhan Tang, Han Zhang, Linlin Fan, Chang Su, Wenhui ZhaoDOI ↗Editorial oversight: Dr. Julia Lee, PhD · Oncology, Genomics & Drug Development
AI-generated summary of the cited source, checked by automated accuracy review.
How we work
Share
Key Takeaway
Recognize lipid metabolism as a proposed mechanism of endocrine resistance in ER+ breast cancer, pending clinical validation.
This systematic review examines the role of lipid metabolism reprogramming in endocrine therapy resistance in estrogen receptor positive (ER+) breast cancer. The authors synthesize evidence across fatty acid synthesis, cholesterol metabolism, lipid droplet homeostasis, and mitochondrial fatty acid beta-oxidation.
The review concludes that lipid metabolism reprogramming serves as a key mechanism for endocrine therapy resistance in ER+ breast cancer. Metabolic remodeling processes are reported to provide survival advantages and energy to drug-resistant cells and to promote drug-resistant phenotypes by affecting signal transduction and epigenetic regulation.
No effect sizes, absolute numbers, p-values, or confidence intervals were reported. The review does not include clinical trial data, and no safety or adverse event information is provided. Limitations, funding sources, and conflicts of interest were not reported.
The authors suggest potential for developing new combination therapy strategies targeting lipid metabolism to overcome endocrine resistance. However, the review provides a theoretical basis for future research rather than clinical trial data, and the findings should be interpreted as hypothesis-generating. No practice-changing recommendations can be drawn from this evidence alone.
How this fits prior evidence
This review addresses a gap not covered in prior breast cancer coverage, which has focused on environmental factors, HER2-low survival trajectories, surgical approaches, immune cell quantification, and exercise during neoadjuvant chemotherapy. None of the prior items examined endocrine resistance mechanisms in ER+ disease. The current review extends the evidence base by synthesizing preclinical mechanistic data on lipid metabolism, but remains qualitative and does not confirm or contrast with prior clinical findings. It provides a theoretical foundation rather than practice-ready evidence.
When breast cancer cells learn to resist endocrine therapy, it makes treatment much harder for patients. New research into these cells shows that a shift in how they process fats is a key reason why they stop responding to medication. This process involves changes in how the cells build cholesterol and manage energy.
These metabolic changes do more than just help the cells survive. They actually provide the cancer cells with the energy they need to grow and resist drugs. By changing how the cell handles fats, the cancer can also alter its internal signaling and genetic instructions, making it harder to treat.
While this research provides a clear map of how these cells adapt, it is important to note that this is a theoretical review of mechanisms. It does not provide data from clinical trials on people. However, it offers a clear path for scientists to develop new combination therapies that target these fat metabolism pathways to overcome drug resistance.
What this means for you:
Changes in how cancer cells process fats help them resist hormone therapies and gain energy to survive.
Common questions
How does fat metabolism affect breast cancer treatment?
When breast cancer cells reprogram how they handle fats, it becomes a key mechanism for resisting endocrine therapy. These changes in fatty acid synthesis and cholesterol metabolism help the cancer cells survive and stay active even when they are exposed to drugs meant to stop them.
Why do some cancer cells become resistant to drugs?
Some cells become resistant by undergoing metabolic remodeling. This process provides the cancer cells with more energy and changes their internal signaling and genetic regulation. These changes help the cells develop a phenotype that is much harder to treat with standard therapies.
Will this lead to new treatments for breast cancer?
This research provides a theoretical basis for future research. It suggests that scientists could develop new combination therapy strategies that specifically target lipid metabolism to help overcome resistance in estrogen receptor positive breast cancer.
ER+ (estrogen receptor positive) breast cancer is the most common subtype of breast cancer, for which endocrine therapy is the primary treatment. However, the development of drug resistance severely limits the clinical efficacy. In recent years, lipid metabolism reprogramming, as a key metabolic feature of tumor cells adapting to microenvironmental stress and driving progression and metastasis, has gained increasing attention due to its role in promoting endocrine therapy resistance. This review focuses on the lipid metabolism reprogramming that occurs in ER+ breast cancer cells in response to endocrine therapy, systematically elaborating on the key molecular mechanism changes in fatty acid synthesis, cholesterol metabolism, lipid droplet homeostasis, and mitochondrial fatty acid β-oxidation. These metabolic remodeling processes not only provide survival advantages and energy to drug-resistant cells but also directly promote the formation and development of drug-resistant phenotypes by affecting signal transduction and epigenetic regulation pathways. By integrating the latest research progress in this field, this article aims to deeply reveal the intrinsic connection between lipid metabolism reprogramming and endocrine resistance, providing important theoretical basis and direction for overcoming the bottleneck of drug resistance and developing new combination therapy strategies targeting lipid metabolism.
